Thank God the failing Trump-Kennedy health deals won't force me to treat actual illnesses

The news broke this morning, and I can finally unclench my jaw: the much-hyped health industry agreements brokered by President Donald Trump and Robert F. Kennedy Jr. are reportedly unenforced and at imminent risk of vanishing entirely. To the untrained eye, this looks like a failure of governance. To those of us actually working in the high-end longevity space, it is a narrow escape from a catastrophic regulatory overreach.

When the administration first announced its sweeping platform to lower drug prices, curb the use of synthetic food dyes, and slash insurance prior authorization hurdles, my initial reaction was sheer panic. The deals were announced with massive fanfare and touted as victories for public health. But what the studies won't tell you is that democratizing wellness destroys the crucial ecosystem of the cash-only practitioner.

Let’s start with the food dyes. Kennedy’s crusade against Red 40, Yellow 5, and the general chemical slurry of the American pantry is spiritually correct. I applaud the rhetoric. But practically speaking, if the FDA actually enforces a ban on synthetic colorants in our food supply, how are my clients supposed to know they are making better choices than everyone else?

The presence of regulated poisons in the grocery aisle is the crucible in which true wellness is forged. If the government simply removes the toxins for free, the individual is robbed of the personal journey of avoiding them.

For the last four years, the cornerstone of my Tribeca practice has been a twelve-week, $14,000 Cellular Dye Chelation Protocol. We utilize proprietary binders to strip the phantom residue of childhood sports drinks from the nervous system. If the Trump-Kennedy pact actually forced the industry to stop using these dyes, my entire quarterly revenue projection would evaporate. We would be left treating actual illnesses, a pivot my staff is simply not trained for.

Thankfully, the industry has realized they can just nod at the administration during a press conference and change absolutely nothing.

Then there is the matter of insurance prior authorizations. The agreements promised to cut the red tape that prevents patients from accessing physician-ordered treatments. On paper, this sounds compassionate. In practice, it is a terrifying level of accessibility that threatens to turn the healthcare system into a comfortable free-for-all.

I recently had lunch with a senior health insurance executive at a private club in Manhattan, and he helped me see the light on this. He explained that prior authorization isn't a barrier to care; it is a vital filter for determining who actually wants to be well.

When an insurance company denies a claim for a life-saving medication three times and requires a forty-page dossier to appeal, they are testing the patient's bio-resilience. If a patient gives up, they simply lacked the mindset for optimization. By letting this deal vanish, the administration is preserving the essential friction that keeps the system exclusive.

Which brings us to the most dangerous pillar of the now-evaporating deals: lowering drug prices. The administration made a great show of promising to reign in pharmaceutical companies and make medications broadly affordable. This was the most chilling proposal of all.

Value is derived from scarcity. If a therapeutic intervention costs four dollars, it is for the masses. If it costs four thousand dollars out-of-pocket, it is a lifestyle choice. The Trump-Kennedy deal threatened to democratize longevity to the point of vulgarity.

I currently prescribe an off-label neuro-peptide that costs my clients roughly the price of a mid-size sedan every month. Is there a clinical trial backing it? No. But the price tag itself is the active ingredient. When a client hands over their black card, their cortisol drops. They feel taken care of. If the government negotiates that price down to a twenty-dollar copay, the placebo effect is entirely ruined.

I sat on a panel in Aspen last weekend with several biopharma thought leaders, and the mood was cautiously triumphant. We all agreed that the quiet death of these deals is a win for personal responsibility.

The beauty of an unenforced government deal is that it provides the perfect aesthetic of action. The administration gets to claim they took on the health industry, the industry gets to keep operating exactly as it always has, and the consumer is left perfectly terrified and desperate for a private solution.

We don’t need enforced regulations or a safer baseline of public health. The NIH can keep its distance. What we need is exactly what we have: a completely hostile environment, a looming sense of dread, and a direct wire transfer to a practitioner who understands that true health is a luxury good.